Journal: Journal of Ovarian Research

Article Title: Trophoblast cell surface antigen 2 (TROP2) from ascitic extracellular vesicles drives peritoneal metastasis of ovarian cancer by mesothelial-to-mesenchymal transition

doi: 10.1186/s13048-025-01845-6

Figure Lengend Snippet: Mesothelial-mesenchymal transition of peritoneal mesothelial cells induced by ascites-derived EVs. A TEM analysis of EVs. B NTA analysis of EVs. C Western blot analysis of EVs markers. D Dil-labeled EVs were incubated with HMrSV5 cells for 24 h and then observed under a fluorescence microscope (Dil in red and DAPI in blue). HMrSV5 cells were incubated with EVs derived from Cancer EVs and Normal EVs, respectively. The PBS group and the TGF-β1 (0.5 ng/mL) + IL-1β (2.5 ng/mL) group served as negative and positive controls, respectively. E - H . The protein levels of E-Cadherin, N-Cadherin and Vimentin in HMrSV5 cells incubated with Cancer EVs and Normal EVs. I - J . The effect of HMrSV5 cells incubated with Cancer EVs and Normal EVs migration analyzed by Transwell assay. K - M . Representative images depicting the adhesion of CMTPX-labelled SKOV3 (red) and OVCAR3 (red) cells to HMrSV5 cells (blue) are shown and adhered cells were quantified. Data are representative of at least three independent experiments and are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: D-Luciferin potassium salt was obtained from Yeasen (China), recombinant human TGF-β1 and human IL-1β were from R&D Systems (USA), and quinazoline (QNZ) was purchased from MCE (USA).

Techniques: Derivative Assay, Western Blot, Labeling, Incubation, Fluorescence, Microscopy, Migration, Transwell Assay

Journal: bioRxiv

Article Title: TGF-β downregulates antigen processing and presentation genes and MHC I surface expression through a Smad3-dependent mechanism

doi: 10.1101/2023.01.30.526196

Figure Lengend Snippet: TGF-β isoforms downregulate constitutive MHC I surface expression. (A) Representative histograms from one horse depicting MHC I surface expression on MSCs treated with TGF-β1, TGF-β2, or TGF-β3 compared to untreated. (B) Representative histograms from one horse depicting IFN-γ-induced MHC I surface expression on MSCs treated with TGF-β1, TGF-β2, or TGF-β3 compared to untreated. (C) Relative GMFI of MHC I surface expression on MSCs following TGF-β treatment with or without IFN-γ stimulation. Data shown are mean +/− SD for n = 5 relative to the unstimulated and untreated MSCs. Superscript letters indicate significant differences between groups, p < 0.0001 by ANOVA.

Article Snippet: MSCs were treated with TGF-β isoforms by adding 1 ng/ml recombinant human TGF-β1, TGF-β2, or TGF-β3 (Biolegend) to the media for a minimum of 72 hours unless otherwise stated.

Techniques: Expressing